REGISTERED COMPA14Y NUMBER: 11943477 (EngI￿d and Wales) REGISTERED CHARITh NUMBER.. 1185091 AtKIIthQ Rnondal StsteThnts Fdlb¢ular LJrynphorn4 Found*lon {A Company Llmlied byGuarantee *ACWJ2VS' 2810912023 COMPANIES HOUSE A75 Hwne5 Watt5 WC1X 8TA F￿11￿4•1 Lwnphcffta Foundatlon Contents of the Flronelal Statem fort￿year enoed 31 December 2022 2 to 7 8 kn 10 11 Slat•m•rt ¢1 Flnandal P￿711¢￿ 12 13 14otts to the St#t¢m•iii of Cash Flows 14 Wotes to tht Flnandol *alem•nts 15 to 22 Foll1￿￿• L￿￿PhO￿a Found*lon Reftle￿ and Athilnlstr4iNe D•talls forthÈ year tnded 31 Deewnber2022 Tfttstees Lwd J N M*thls01 Lady N S V￿￿￿S0￿ PmVT￿ffiP￿ AWtN J J Pojrfey lapwnied 1517f2022} Dr J W Swnon5 laFpJffti•J 1YTf2tr221 s￿73 Tlwb¥lds Fload WC1X 8TA Reqlsttf•d eunp•ny nwnber 11943477 (ErWwMI •vJWales) R•glsternd ettarlty mwnber Audbttrs H•r*sW41s Oenwent Hcd 69-73 TheobAlds Ro•J WC1X 8TA FI￿1 Folllcul¥ Lymph¢￿• Foundatlon Foiiicu homa Report oftt* TnJst•es The truBttts who we a30 directh of the dwty the purposes d Ihe Cl¥n￿lEs ALI 2C(fj. th•r report the finaKiel st•t*xenls ol the rthnrity fLY the Yew to 31 Dwiber 2022. The trustevs have adopted the prw$ions of Accounting and Reporkng by Ch*riie5". Statwnerf of R￿miM￿lJed fvaciKe zFfdicaNe lo th8ritie5 wepariTro lTrwr ?￿oUnt$ in o¢cLYdanre Trwrth the F￿￿{la1 SI￿rd the UK and REpublG ol treland IFRS 11Y21 (effective 1 Januffj 20191. Objectives and activities Our rni5sion 15 to help those +Aith Fcdli¢Llar L)￿c￿3. a C￿lty bkoj cartw. wdl and gBt well byfindino and Ilmdinu the best tolknd breaklhrwts tr￿1 (*zTrJe hcttl ￿[￿￿Sta￿j and treat 0jrth.￿. We provide Follrultsr Lymphoma fooJ5ed Inforn￿ti￿ resourcu f(Y to ￿SUre ￿"¢Al¥. are •1 th* hE#rt of the search l¢y bthr trtalmenls (#n. More Ihg ¢hari&e5 otriethes aro r85tyKknJ trJ F&1￿1•r L￿p￿rn iThJudiTrJ sp¢￿ Ihe estsbhslwnert of * wrteffl￿ ¢1￿1￿¢ to and ¢*n￿ r8sear¢heT5 lofocus on prvspectyv• Gures. patient r*TrrnuThbe5 an¢J •14uatiry the crf pati￿t reFuled c*Acwieson current Ireatments ¥de effects to assst dinitians and paknts. To imwove hea#h ￿t¢￿Tres by way d 51inul*"r4 researth •xl of ))m￿¢Mentsry Oxdit￿Th$ to supplernent M￿￿al treatrnent. 2. Achievements N¢w leadersNpiogulde ¢wrmtssion In Juty, we wdryyne(l att4)mphshed CEO K2t• RfrJ•rs to leal ow rxgarozatKffj into the fvrtwe. Kate brings eXceptic￿al vision d expertsse to advance our stratèJK di￿￿On th"vÈ rn￿10n IC￿9rd. Her and havg u$ pc4 for oven ure*r ad*evemeffls ahvad. Eslabllshln9 esteemed adv1$￿ b￿ftts Rwnisino the importance crf ￿v¥S¢ persFecb'ves. we estsblshgj nv* Life sa.en￿ 8NI lYnph￿￿l IrlonTrali¢s Aig¥isory Boards. These boar¢Js pYov¢de invaluatle gudance lo our research dev*)menl inits'ab've5, *ith 8 fctus on the PrKisb?n MediGin• Prlyrammo. Ther m￿￿￿.5(1￿￿ry • help wkxe inrthats'vo approach85 to adv￿￿lA9 ¢xr understanLlng Off￿1(#￿¥ lynpl￿1& Strenglhtnlng our boanl of ¢nJsthes We warmly wdccffled Jess Burley and knatrAn S*nons as ￿￿truSte•S in 2Wf2. Th•ir kn￿ed￿ *nd eyperienc• furtW enrich our t*)ard and cL¥itriMe divEtse tyowl ￿rMIsS￿￿. Amiounelng Inaugural CURE FLAward rKlp*nts In Decembtr, we marked 8 si￿￿¢an• ffile5tone by ffitsi-ever CURE FL Award recipien15. ath1ev￿nenI signals rnearnngfvl progress in our cunmilmem to acrekrate le￿r¢h and firKI a ft)liud¥ ty￿￿hl￿a VATe. The CURE FL Awards afe not yow typG#l they 8 catatyst ch*we In fdkLd¥ researth. Our aim is to a¢xelerate breakthTowhs dwect pati&it benefit le6t￿￿ ￿r￿￿¥811t￿ lI￿t trans*orms Ihe FL landw2p8. Thr¢xJoh ¢ollabcKaticfi, we are bringing re5earthers l(gth. ¥h•rity irtsig1*4 ¥•h'ng ¥lpa5. ar￿ tsN¥edibThJ irnpxfful thstsweries for FL pall￿1$. Connecllng *llh global experts alASH 2022 Ow we5ence at the AJ￿eri￿n Socjety d Hawnatdg3y IASHI C¢￿18T*￿t pmide&J an impa￿￿ oppytunrty t¢* L￿r￿1 wfth the lymphmia c¢mmurMty. We ex¢harged inswJhts. forged ¢dabcration%, and shared ourdeth'cation to a(fvanang I￿phoMa knowfedge and patr"￿t ￿A¢c￿e$ Inthau¥es. We also US￿ Ills tNe balance of £16.401. The tharity isexpxtingto £2(m).0￿ ofreslrthl ir￿(Mel￿ 2023 dearng nryab"v• balwt• of£16,401. The orgwisabon operaies *ith lin11￿ ovetheads. The Tn￿￿e$ have detvrni￿d Ihal th& r8S8r¥es twgel should be at the levd of 3 months, •4)eC￿ expendrture. 8udgetaJ eXpeThJi￿re in 2023 fiwLial year s in excess of £2m. and the Truslees ha￿ set a twgded resaNes fwe d £SOQk as at 31 Oe£em￿ 20t2. 3.3 Going concem The Twsiees t¥Jnsider that tt is 3ptYopriale to wep8r• the st*ments ￿ a gory concem basis. Tr gL¥ng cL￿CeM assurnpton Is bas￿ on an exisbng ￿0ft aryj In place covenw penoj to Oectrnbef 2023. A nwl >year twdgeUI(x#4st 1$ bwj draft•J whKh ￿ radLKe extwnal w5ts ar￿ vol sUbda￿allY rwjuce annud d•fiats. In a4dth"on. the TNslees to mvesb"gat¢ to enhance th• lonfrterm sustw"nalilty of the charty an¢J identfy those areas where thE perfo¥marYx Gan b¢ imprrN&a. *ilh xtiorts bu.ng tak￿ to rthGe defiats. The e5tablishmenl of a S￿Iled teurn of ￿anent ejnployees dem¢)nstrates Folivjlar Lymphuna FouTrlation'$ nmitsnerrt to the opwalion oflhe Charity a$ 8 gclng ccrfwn. As a res￿1 of thèse f8dty5 ¢he TN*s eonsider the goino onrem basis to be apprDpriaie. The Fr>lli¢ulaf Lymphoma Foundation 417 Finchley Road London Nw38￿J FR UNCTrR41ShNG EGULATOR 410)203d17es83 Folllcular L￿ph￿Tra Foundthn Folllcu homa Report dth• Trustees foritte y ended 310e¢omber 2022 3.4 Principal risks and uncertalnties The trustees have a duty lo ldenb.fy we4V the risks trj w*u"ch Ihe charty is 8￿j tr) w￿ure apwo&Thte ctffilmls are in ￿8¢¢ lo wo¥Kte reasonatd8 a$9￿alKS W tra￿1 aThJ The INstees have assessed risks to *lMch tht is e)¥os¢d sati5fivJ that systvrns ￿ in pla¢e to mthg*e eXF*xwe to stth rnw risks. ProGedwes ar• in pla￿ lo ensure compharte *ith W aThl staff. vc4unleern. dients. and vi*tor¥ lo the gar*s2tb)n. The Chwity h•$ th* appwatt l¢vel of insuraft¢¢ to meet rts ot*gatths fft respeci of ¥nploy¢es and 3.5 Future plans 3.5.1 Plans for the next 12 Months Our orÈ8s offrfftts". Dellyerfng knpa¢i through fvttustd ￿$*￿T¢h. ¢I￿n9 thg qap6in FL re5earth and dr￿ dv4fjlpwn*t IlY0￿h lh• dual arvoath ￿¥￿s1On'0*1d•nc•-￿a6•d, FL infomab'on and invesbno In the most prrJni%ng uJattve research. Devel¢Jpirw new treaimwty arKI oire$ 10 FL patwi$ ty>t ¢Yeating a p*hw•y vith rapKI 'benthto.bedsMI¢' devekspments. Collaboratlng ¥Ath lh• b•st Rdath)r%h'ps are key to Ihe success rf Ihe dwity. We map eyi51iThJ aTrJ nt4V ￿T￿unite5 for p*thershiF6 at on intemats.ond Iwd, bLyIth"ng rm uihc41 h"r*s ewrt¥. Sci￿￿ rexarcher5, •nd philanthrpp¢ domrs. Growlng luntha151w lfteom•. Raisiry tur￿5 is e$￿11¥ kj en5UTing w stratwc mwjl￿1 prCwrr￿S and that we havE the ffinon(ial re8ourc¢s av*labl• lo Carry the necewry scienffi¢ research io find • ￿re. Wt stn.ve to mantain and buiFnising tr¢#tmenl options and pnjpelling u5 doser to finthng o we. By levtywing data. induthno b"clowl infcrfmatirfft. W8 seek lo pioneer a¥enues in FL research w¢J ¢JrNe trt(knannawJbcal and iNJu5try dw Unders&Mdlng unlque blologyfor Per￿￿1$ed ther Al the ojre d the PMP is urnl¥standino each Pab￿rG Oth"rKt and ulltsipo this krvAedge lo pratd the most elfecbvtr. t*bred Iherapeutic cplic￿& Tr Prec￿￿ Prpgrnmn* WW be • reswrt¥ d gpel v8kne to rese¥¢lws &nd tth•tety l¢+ emblng end acceler81*¥ cl*JulftseJffjh•ndlMl& a ¢we ltyFL" Dr Mttchell Smlth. KI*Jk￿l Top re5earth yiorltks Lth¢Jttstsnd th"sease hetwr>a8n•ty. Optimp5e trealment regmèns and 5•4lkryltYig. Profile and yedid treatm￿1 tOX￿￿Y. r)8vdop swrogate wdpcints (for imwD¥•J ¢b"nK* tiial doww) Genwat¢ prospective real4￿d dala. Comwe￿N$1v¢ Infomiallon fax FL This prqect hiThJes on *nassing the largest re[*￿ d fftknnaM>N cffj FL, dr￿$. resear¢hers. and patients wfth a nthrfound under*anding d Ihe th"sease. 8y Iw4ryng thi5 Va* datas*. * can dn.ve forward wowe55 and transr Ihe la￿SCape rf FL r85earth and treatrnt¥rt. The Folliculai Lymphoma Foundaiion 417 Flnchley Road Londo NW3 6HJ FR FUNORAIgNG REGULATOR dlQ1203d178583 Follleular Lym*￿la Foundthn Foiiicu homa R•port orthe TThstees fortmyear en￿d 31 Oecefflber 2022 3.5.3 Targeted Aceelerated Research (TAR) programmes One key area for the FLF is tttw8pw&c devel0m)￿l iThbab"t&*S. ¢an a￿anC&y and tranYatsor4 TeseaTth. ro date. tho kYLyess in th¢treaknwrt d FL has bEen fntstr*"Wy sluw, *ilh fvndiTrJ aThl Our 8Uito of Target￿ Accdevated Re58arch ITARI iThbati¥•s ain tts mako ￿al.¥0 IheraFqes awilthty to FL P￿t￿ts •5 8¢on as poss*4e. thjr TAA Fwammes ￿1￿ce ow wwess tiyward% our ff*56K¥) by investing ￿ thv tru"ghest ¢olibre resetr¢h pronisng iM￿jrate to Ihe patent (CURE FL Award51'. ¢Yeating aoteoc P*ther5hips wilh top inv¢sts"galor5 and insl>tths artyjnd ￿ W￿lId Icentres cl Excelkncel: ar¥J enS￿1Vj we dony mts$ out OA urnque hiih.n$k, hi￿r￿rd 0ppwt1m￿e5 IOFfthmty FuThll. CURE FL Aw4nls Prngrme The CURE FL Aw*d$. laurK*&l in 2022. we a uniy rtsear¢h b¥ntyThJ Ic98th4¥ scaenli5ts re3earchers world%*ide. Tlyouth irw)OVativti iyoiecls, wo arn b) s*iftty advan￿ d*4r41 lrials and effecttve n therapies fLY pabents. Addresslng the need fvr more Tollkular l>Thphoma Rsearth Fdlicular I￿phOMa 15 clten overshajowgj cL￿ar*S to cther IJITw￿￿8$. ts 8f¢yww progr￿lun and trtal Mtetthe 2022 9ran¢ees In cdlaborAtion w• ¢¥thlLv sdKlod kY¢pJsals targHl•ig k•y IdlipJ￿r tymphcffla n8•J6 it"%ng w.ent inleFe5ts and diThcal aFf4Katif￿. After a knonth invc4wfftg *xperts and pati¥ts. w• I￿￿¢￿e￿ the most ￿l￿ng wr¥ects cxrt 0120 We are tmlled to introduR our first tywtees and the* excits"Tha resethrth weas. &h has been awarded up to $9]OK ov fvxs ye#ts. bwnrring Oecembor 2022. Tru$ sbJnth¢art in¥tslm•rt m¥ks an in1￿ stride t￿ard ¢w rn1￿£￿. The Foll1c￿r LyTht*oma Foundabon is honoured to surport the CTitscat M)Jk of the fdlowng pioneering researchers vkno were sdeeted as the inauLwral CURE FL Avrards grantees in De¢ember 2022: n5¢uldo endel ori* Sloan Ketterin ca￿er '. A rw $6gr•l me¢haThsm IHVEMIBTLAI abnoThal in 90% of FL cases and imF•rtant in Ihe gernss ol FL has beem idwtfjied by Or *d his wp. This make5 HVENVBTLA a IN'￿-Value t¥rW 5Fe4fi¢ to FL. CAR-T cd15 that atlAck 8118 cdls are an exciting ntw treatmerrt for FL. Tlws use CAR.T in a dDYerenl way, lo S[*￿fical￿ attack t1￿"S FL4p*fic pathwBy. The goal isto Iw¢ • tri•1 ofth¢s¢ r#)vEI CAR.T¢41s4¥th fty patiwls by the the wt wod. Dr Joshua B Icahn Schcd of Med'one at nt Sm ' US.. CAR-T eelL% •r* * excellent treabheTrt fcf scffie patients Wth FL but do not ￿rk fw evuyone. Dr W4. in immwK+lherapy of and hi5 te8m hèvè that by4#nder c811s that th) e￿leSS the CAR-T l¥gBt we one mechanism of CAR.T resislance, d Ihal they may have a to overcane Ih"s. Th•"r *￿￿Y may **ll 1*1 lo a &"nKal knal of G4R-T given a drug tthat wll enhance the kilir#J d these bystwKler cdls. 4nwo%ing outctsnes fu patients. ". Dr 8Wln. an expwi bK4oJy, with h dinul ts)Ilab)rat¢rs. *ill r£￿Idu￿ knas (3>niiThng W9Wic-targeW EZH2 ithiL¥tot5 immunolherapy (CAR-T or btsptitific anlbothesl. or ￿ 8poOosiS.t￿ BCL2 ?n*it¥try>. Usjng LM1q￿ FL mouso models and pationt sampl85, she wll stth 0￿￿*.￿3th0n5Oflaf9al•S thwapos Wth imrNncther8py. inc4uth'rvJ imp* on bDth FL B c•116 and its mi¢xoeNmnmrt Tho is ￿ derm to imF¥¢walhwapy in FL Leading this Spani$h 0￿p with exten51ve dinic￿ ewence dv4eloF*ng CAR-T Ir¢alment Tlw dewl¢)p new generation duaktsrgete¢l CAR-T cdls, ed1$ Ihat crfy lyThphL¥na felL% tArt the swrounding Micr0en￿r)r￿MenI that helps keep FL c*Us ahve. Thv4 W 10 havè• ofthe b85t CAR.T reaty by Ihe ofthe gant pen¢>J. The Follicular Lymphoma Foundalion 417Fsnchley Road London NW36F ¥J¥•*.Iheflf +44101203d178583 FUWRAISING REGVL4TOFI Follkulx LyTnph¢fft• Found Foificu Report of the Trustees forthe ytrarended 31 Deeember2022 Ac¢elernUng progress and Impact 8y allocatino $2 million over ￿ yea￿. Ihe ¢VRE FL Award5 wopel u5 doser to b¢tler t￿0￿￿$ and 8 ojre. We aim lo elevate f141ieLa8r fymphoma's $￿Jn￿8n￿ in drwJ devdcpKni and t•e t•.1we￿ therap%8. Ow swl k* to bring hq>e, opporturilies, and ￿ltsCa1 treatrnent insigtrts lo patienls dI￿an5. FLF ¢entr•s ol E¥¢dlence ICOE) The FLF proudly Pres￿15 the Centres ol Ey£dlerM* ICoE} wcywnmtr. * (¥wng init￿"Ve that fvges pwherships with major acad￿1¢ aThJ research institltiors %•rthide. Tlis wogramme harr￿sseS Ihe o)leclive expertise cl estewfitr instrtuttws. SP￿nVbg vari¢x￿ th6(iFdin%. tr) ynpany th"mit•J The ¢￿panY was e5talAi5hed c*$ 12 April 2019 uThJv a Al*mcffar￿￿ cl wthidb deternne& the obieL* and powers ofthtstharitabl8company and is govemed Wmlor itsfvrt.des of As%>raaOon. The Charilab￿ C￿￿Y w•s rryistered the Cl•rty 29 2019. 3.6.1 Declslon rnaklng The Board of TnJslees meets 5 time¥ w year and 19 respmtit ly thteÉ•c ar￿ pow ofthe Gh￿"ty and for monitenng th8 rnariawent 8Th1 of seThIc￿. 8oard M￿be1¥ we from a voriety of p1cl￿oI￿1 ba¢ktyounds relevantto the work Lrfthe d•. In 2022, tha Bowd l*s recri¥t8d adthltonal TNslees lo its sldl furfherin rwion of the grth￿ th'ver*fication of Ihe ¢hariVs 8cts"viies. The Ch*ity app)inted if$ first CPi¢f Offw in 2022. Th8 Chief Operating OffKw 15 ddegated to dea *ith day-trAay ¢)pvJatwts. 3.6.2 Statement of trustees. responsibilities Th¢ trvstees Iwkl are aso the ¢Y￿Cto￿ of FdlKulw Ly1w￿￿a F￿ation for tho purptses of CL¥Trparty lawl are responsible IOT wepanng the ReFQrt ¢Y the Tru*e85 and the finanria Stalwn￿ in aCoxd￿Ce wth 8ptylcable law Unitej lQngdrMn The Folliculor Lymphom& Found81ion 417 Finchley Poad London IW36HJ Into@Ihefl1.￿g FR FUN[)RA￿￿ REGUU4TOR 444 IOIt094YID￿5 Folkular Lyrynphorna Found•tlon Folllcu homa Report of the Trusttes forth•year ended 31 De￿rnber2D22 A¢￿￿nI6[V￿ &andwd5 (V￿ed Generalty Awted A¢axnbThJ Practi￿) Indu¢fty Rewl#Yd Standa 102 Yhe ReFu*'ng Slandard apr*abte in the UK Rewbé¢ ¢4 I[dan￿. Ccffiwy r4uires the Iruste85 to prepare fin￿1>￿ *atem•ts knr each fmraal y￿r *tich giv• a tvJ8 and faw wew ol the 5ts1e ol affairs cl Djngany Ihe }r￿1￿j rexM#ces akWiGabDn ol resources. indudiThJ the income and eXp￿dthre, Gl ihe ch8nl8ble l￿mPanY ts th8t [￿. In Fwaring those finarL1￿ stsI￿ents, Ihe tn45tee5 are 1•4uir8d to Sdert $urtat4e kxliries ¥rKI aswy than w*5knty. Obs¢rve Ihe melhods aTrl wtriupTres in the Ch¥ty SORP. Make judg￿￿ents esi¥nales thai we reas¢¥MNe and State Whet￿r 8PF4icablè standards ha¥• fdh7w¢d. ￿bject lo any departWe8 di8dos•J and expl8ir*l in Ihefih2n¢ial staiemeAts. Prepaf• the ffinanod statwnenfs ¢Jn Ihe cr*Kern b￿$ unl¢ss it isinapprwth b ryrne th)t Ihe chaTTrtable ompoThy will ￿ltin￿ in Imwess. The tru4e8s are r8$w￿$lble kerfiiiio propw attOthlirvJ Trc•xds dis(1058 wllh reasonable axura¢y ai any tine tr rinanLI81 pos￿"0n of Ihe tharitable ccffjpany and lo enat4e them to *xure Ihat the fih8ncial *atements g)mFly wlh the Companies Ad 20CA3. They are aso reswLEible lor safryuardmg the assets of Ihe th*ilatle (wiparry and h8n¢e fr*r tsli reasonable stW5 for Ihe pr￿t￿￿ and detectK)n dlrdud aThJ ottw iffewlwi1￿S. So far asthe trustees are aware: There is no relevant wJdit inlcthiakn dwi4wecoTrparf5a￿510r5 are U￿￿ore.. and the trustees have tak￿ al 5teF6 that Ilw to have t*en to rn8ke of 8ty rdwant 4uth"t 4. Auditors Report ofthe trustees, inDwats"w a strategr reFryiwhtyTr8 Ftsjndatth 'chwit8L4e D)mp8n*l ft¢ year ended 31 08￿ber 2022 W1￿Ch comprise Ihe Staton￿1 d Finanraal AcbTrAties, the Sl*emenf of Financ441 Pos"tun. d Cash Fknvs notes to the st8tèi%rts. ¢nduth'rMJ a wmm¥ry tsf signrftont 8cc>Junb"ng pdiue$. fmanfial repoth.ng framework that has ap￿1*1 n thar preparatrth) 15 ap￿iCatIO law and Unilod lfjnud Accounting St8ndards IUThted Genwally krepted Ac¥3)unting Pra¢*"r*l, Finanoal R8wtirvJ Slandwd 102 Tr R¢portsva 8laThJafd appbrth in the UK and of IreIar￿'. h) our Ihe finar￿￿t #at￿ents." give a Iruo far View of the State d Ihe chanlatle affars as at 31 December 2022 and ol lis inC￿1r r•sourcas and apr4¢atth trf ￿$￿￿¢e$. indLwth"ry rts inCLYna ev￿ditUre, for year th¢n •nd¢d", have prOp￿lY prepar•J in acwdaTr2 ur*t￿ ￿￿jd￿ Generally Accept•a Acuunbrvj P￿￿'Co. I￿1UdIruj Flnanc•a ReporDng $18TrJ8rd 102 The Anar￿1￿ ReFabr¥J SI￿d￿d apl41cab￿ in the UK and Republrc of IrdaTrd': nd . have be4n w¢F4r¢d in xc0rd￿*1lh the wirements rflh• Crrnp•iDes 21Th. easls for Wnlon W* ¢ondLKted our a￿j(¢ in acc4)rdaw Intwnal¥M•l Slarkaards on A￿¢￿"ng IUK) IISAS IUKII and ap￿1¢at* law. Our respM*bilib"es lkne staTrJwth are lurthar descnbed in the A￿1￿¢￿5, reSpJn%b4￿8S for the audit of the financial $taiement5 S￿tIOn ol trjr W We ir¥je>w￿eTrI cl Ihe ctsit&4e 0)￿nY in ac￿darts *ilh Ihe ethical raqurements that ar• relwwt to ow *udit of thg firontia in tha UK. thè FRC$ El¥cal Standard. and we have luffi11￿ ¢yJr oth¥ ellY"cal resportst*"lths in ￿(¥danCe wilh Lh￿ requIrern￿. W? bdi¢v¢ that Ihg awtht evidence we have Obtain￿ 15 and apprcpriate to pttyKl¢ a bas$ ow ¢•rrion. Coneluslons relallng to golng c41nC In 8udibW theflnarKial staternents, w• have conclLwJed thatlhv Ilu￿te< useof caKem baws ofxcwiling in the preparatK>n of th¢fin8nual StsI￿en1$ is apwowate. thal, indivh4uaUy ty ¢dle¢bvdy. may ca* sgrmficont on Ihe thariiatrle c£thpanYs ability to ojrknnue 85 a gThn9 concem for a pwiod ol at l•a5t twefv• rnorths from finanual statemen1$ 4t0 4ulhoris6d kn issua. Our re5p0ns1bfliti￿ aThl the respo￿1**"1￿$ of the trustees *ith re5Fttt to Conc￿ are deS￿bed in ts relevant sed*)ns oftPAS rw. Olh•r Infom)atlon The trystw are re8F4MsiL4e for the ther wrfiThalion. The othtr ¢L¥ryrises the Inf0Th￿ induded in the Amual Report, other the slaternents ￿ ow Rryort dthe hJe4>uwJentAuditors Ihereon. Our opini¢Jn gn Ih¢fin8noal statements does the Informats.￿ and, to the t¥iert 01he￿ls8 8xplKi Stat￿ in our ryrL w* dc* not 8xwo8s anyfr)rm ofaG9Jrarts ccfidusion ther￿Th. In connecbon wth •w*t ol Ihe fmaw?al *atem¥bts. ￿nSit￿ltY is lo tr* other fftfomntro) and. In ¢thg $0. onsider *t*ther the othw Infi¥rnatr'on materialy irKODsi5t￿I the finanL7a statuneTrts ￿ our kn￿￿edgts obtanffjd in the audt ￿ othemse appears to be materialty mBstated. W idenlfy suth matersal Incor￿sten￿e$ or apparent matertal m**aMients. we are reqlqred 10 delwmine wthelher this gives rlse ￿ a m*erial M[￿alem￿l in the fimnraal statements bhemsefves. W. bas￿ on the h•Ye p¥lmtyJ, we C￿dude tha¢ there is a material misstafwnenl ofthis ¢th¢r inforniation. * a￿ f¢qLAr￿ to repxt Ihai lacL We hav* noYy'rv4 to r¢ptyl in th"$ r¢gard. Oplnlons on matters pres¢rflJed by th• Comporfes Act 2001 In rJJr wnion. based on the work uTrjLYtak￿ in It* ofthe a￿t". the infrnnaD"rffj given Ihe Report of the TnLStees fe* fina￿￿al ye*r fry Ihv In*K•l stsli¥htyts *r& prepared is ccfflsist￿I *ith ther￿an¢jaI sl*unen15", arnj . the Report ofthe Tntstees has been prepared n ￿¢￿dar￿t*￿h apFknLleleoal rrfu1r￿*￿. Folllwjlar L￿￿Ph¢ma Fourthlon Matter5 on whl¢h we are req￿red to report by •xwJon In the [￿ht olthe knty￿ed98 undersi*)thr4J of the thariiable e£rfnpany * tts envyonment obtamd in ciwrse of Ihe audit. have not idenithed materid misstatemi¥iis in Rewi of the Trustees. We have ￿t￿"n0 to ry**rt in respec* matt#5 the Ccfflpori85 2006 rquires usto report b) you ow opini¢m". br8nches not th$itsd ty ￿". the finanaal statwnents are not in aWe•n￿l7￿1h tr* acctyjrdty reA*ds atsj ffAum& certain th¥doswES (* IDJslee5' ra￿UneratiOn speofied by Lqware not made.. w• have not r￿•¥￿ all the •vplanAt"o￿ wo fmuiroforw •4bJiL Respon51bf111kn5 ¢1 trustees As explained more fvlly in the of Tryst¢es' Resp￿51￿"￿￿*s, Ihe trLotee$ 17kn aTe dso the dYe¢t¢Ys ￿ thÈ charita￿e company for Ihe ptswes of cclnpwy bwl 8￿ resP￿￿11￿e for the prwrabon rf Ihe finaniyd slalwnents and for being saJsfied that Ihey gNe a Iwe la"r ar¥J forw* ir*emal cc¥*fc4 asthe trustees detennine 15 n￿eSSary to engblè tht prepar&tic￿ offi￿￿(481 statwnwts th#t We free from missw*n*L *thether due to Iraud or err+y. preparing the sl*8menty in• InJst•es ¥* fty assessrwJ tr* ¢kn•rt*1o ats.ltty to ntinue 4$ a ooing o)nwn. Osdosir¥J. as appI￿￿e. m*ters re18teA to gung CO￿ and usr*d the gcwy c4ncem ba6is of acMunb"ng ￿1•$$ th• t￿t￿$ either inleThJ to liquidate th8 chalita￿a ccfflparry or lo caasè opeAtions, or have no realisb"¢ alterrrttre ixrt to do 5 Our responslbllwes lorthe audlt of the flnanclal siatements Our obiective$ are lo obtain reascffth asswarte ￿eth•f the Slala￿ents a5 8 fr•e from material mi55tato)ienL ￿trTrEr due LY wr(Y. and to a ReF*yt oflhe IndeperthN Audth that includes O opinion. Reasonable 8ssurwKe is 8 l¥gh lÈvel thl assurance, IM is r￿t a guwanteé that an 4￿rt Gonduct*d in 4¢¢4rd2nce with ISAS IUKI will aways dei¢¢t a m*wial mi85tatwnent ¥kneh rt ￿$t$. Mtsststwnents caD srise fr¢)m frthjd or wror and are u)r6iderèJ motenol rf. in¢*¥klualty or in the aggregète. tr*y could rea50naW be exFeCted to inflUer￿e lTheoU￿rib¢5. indudiTrJ frawl. •e instances ol with laws wl*"<¥)s. We d85ign prDcedure5 in ITh7 ith our respon5ibil'th*. ￿jIbn￿ 4tA)ve. to de￿ fflater*l in respectof Irr￿l￿a￿.e$. includina tratsd. The exlent l<¥ tyJr woG*Jures are capat48 ofdete¢iTrJ irr•aul¥ilies. Iraud is detaled bdtr4.' W• ￿ned an und¥stsndng ￿ Ihe Wl rwAaW aPFI￿Ne trj the ccffi￿Y the lTrJLStry in whch it oper8tes, 8nd cons¢der•J the r￿k d acts by the ctynwy thal c 1207.504) 116.4011 1223.9051 1.043.¢Jg8 R•¢onclllaUb)n of lund5 Tota I￿$ bro1v￿1 fcyward 1.399.425 1.399.425 3&S.337 Total lunds ¢affl¢d forward 1 191921 1 175520 Contlnulng opeTatlon5 l income anil exp*diknx• has arisen **1￿88. 2023. Rtstlkl￿ ftH￿S R85tn"cted Dofial fwKls cam•d fiward Lrf£16,401 ￿ bÈco¥er&l bytohYhAt*JY multyear •ft. s*ond p•rt duè kn 2023. Foltlcdar L￿￿ornI Found*lon IReglster•d ThAnlxr. 11M347T} Sl•temerrt of Flnandal Posftlon 31 Oeonber 2022 2022 2021 Flxed a55ets ran￿￿4* ¥ssets 7,033 12 57,7e6 22,775 1416 474 Cash at bank 1,439.X 1.439,249 Credltors Amounts du• y 13 1270.7211 145,5201 Net cyrrert assets Totsl assets le55 ciirrent Ibthlft*s 1.175.520 1.399,425 NET ASSErs 1.399,425 Funds UnrestriLxwJ fun(15.' Genèral fund R8$trict¢d lynds Reslricted 16 1.399.425 Total fvnd$ 1 175 520 1399 425 The fin8nrytl atattsments weYÈ apwoved by the Bowd rf TnHlees and authLYxd IDr issue on .. and *ve ils behaff ty. Sep 27, 2023 IIFrtdd50Thnl5qp27.J0230a".33GMT•Jl J N MoTrJelsth. Tntsl¢g Tr* nths part rft*s•fjrArK* siatemtyts P*J• 12 F￿1￿￿•1 L￿nph￿O F(pundatt•n Statem•rt of Cash Flow5 for theyearended 31 December 2022 2022 2021 NDtsS $h flows from op•rallng adltthlts Cash genuaw 48 4521 913 908 N¢t eash (Us￿ iiywty.ded ty operthg aBbMities 913 9)8 ¢H$h Ilows from Invesllng admues Purthase Oftarvib￿ffixed assets Intwest rec4v¢d 14,&)01 1.819 15.6471 37 Net cash u50d in ¥hv¢sb"ng a(*"viSes Change In cash aTrd cash ery1Val￿ In th• reporung portod Cash and Gash equlvalenls at the beglnnlng vf Ihv WEPQrtlng perlod 151.4331 8.298 1416 474 cash and cash equIva￿fftts atthe end tht rèponjng pertod 1416474 Th• rnt•s •xm ￿rtor￿e ￿￿Trial ststtrnents Poge 13 Follludar Lymph(Tha Foundatlon Notesto Statanent <4 Cash Flows forthe yw endtd 31 (kteml>er 2022 Recon¢lllaUon olnel leyj1￿￿￿￿*1knCtyDe1￿nVI c45h wrailtvj aciivlti 2022 Net lexpendturelllKome forthe repwithll ￿rfo￿ las per Ihe Statement ot Flnan¢lal Acllvlllesl Adlu$tments for. Deweuation charge5 kntvest reeaved kncrease in debtU8 12fJ.9051 1.043.088 1578 1371 112,8641 11,619 134.9911 Net cash {used Invwlded by opernljo 913.908 Anatysls ofcash ￿ ush equlvalents 20 2021 Notice dry*xits (less Ihan 3 mcrtP£l Oeficrt in resiricaed reserve 1.381.442 164011 1.41Q474 Totd cash and (*sh equwth 1416,474 The chaiity is eXp￿tir￿j to Terni￿ £2￿).0[￿• of r•StrKtedw￿Mo ￿ 2023 d￿￿1￿4 bal￿¢• of £16.401. Anaty519 ol ¢hang•s In n•t frjnds At 111r12 Cash flu At 31112ra2 Net ush Cash at bank 1.416.474 151,4331 1.365.041 1 416.474 1 365 041 Totsl 1 416 474 1 365 041 The rntes fom) part offheselrArKlaf slatan&its Pap 14 Folll¢ular L￿lPhI￿a Foundatlon for theyear eftaed 31 Dettrnber 2022 ACci￿ntI￿ Wldes Basls of pr•parfno the lIr￿￿1•1 stat￿ents The finarKI* slziunents d the chaiAaL4e rJJnwy. a puta¢ t￿rrt enbty under FRS 1W2, have been prepared n acry)rdon¢¢ with the Ch*il*s SORP IFRS 1021 'ACco￿tsng 8nd Repth"rvJ by Ch8nt*: Staltsnenl of R8¢Cfflm￿d0d Prath* to tharilies pr8pariTrJ I￿¥ accounls In *ith tho Fi1onLyal Reporti￿ Standard aWicatAe in the UK and RepubM"c of Irel8nd IFRS 1021 lththe l Jarthry 3J191'. Fmanraal Reportir*J s￿dard 102 Tr Finanrial ReFKNts'rwJ Slw)dard aFf4KatrA8 in UK Republ¢ ol Irdand. th• Companies Act 2￿. Thefmantial statwnents have be￿ prepared urtdsr th8 h'storical cosl con¥￿￿"r￿. FdlKul¥ L￿n￿om0 FrJJn¢Jatrm is a ry6vate byguwantee. aThJ a wsterwj Golw eon¢ern The financial slat*n•)t$ hav• be￿ on a bass. The Try*es have revkwed and ¢onsIde￿j relev•nt infcfftwlim. indthlir*J the an￿￿￿ buthjet snd I￿re rAsh rn8k.ng th￿r 88se55menl. Based on these assewerls. 8TrJ Ihe rJ￿￿*t res￿¥C¢S avail•We. Ihe TnJ5tees have that Ihw ran Con*"n￿l0 adoptthe wry Lu*em bass In ryep￿gthe amual rE￿rt #rtd 8coJwtts. All ss rec¢9n￿ed In the Statement ol Fina*ial kb'bitie5 once the ¢harty ha5 Wrtrtkxnemt to the fund5, It. proba14e that the be and th8 arTh)Lrt can be measured reliably. Liatrflfy'es are fectyThsed a exptrh1iiure as w as 1$ a *81 or c4rolru￿¥e 0￿￿8￿"0n c4)mmitting the charity to ewditwe. it is pKtht4e tho1 • tr0ry5fer of e¢orAyni¢ knefits be reAty￿ in sthm¢nl and the amount Lrf the ob1gati￿ me85wed rd•. Eyndrlwe is 4¢roun1￿ for ffi on ar*vuals ba5E and has been d85sfi&1 undef Wdiros ltr*t a￿egat* all cr%1 re￿t￿ to the c*gory. Where CO$￿ be directly atknbuted lo partivJl* hea*rys h8v¢ •l¢¢al¥J lo a¢tiths M a wN*¢nt wbth the use of resourc8S. G￿15 to teen mel at the year thd ¢Yaie we as a cunmthent but not a￿U¢￿ •$ *ywditur¢. trustee meelings 8Th1 the cc61d any *al athKe on gr*ern￿￿ rnatter5. Tanglble nxed a55ets DoPrtciab"on is pr(V41d￿ at th•ldkxiTrJ ann￿1 rates in Ordwto￿718 off 8Bch a888t over its eslwnated h. Computer fquiwnent 33% cffi ra￿1 Taxatlon The tharity ks exempt frun ttx on Ns trArltat4e Fund accounting Lknreskn"d&l fvnds can be used in aco)rthroJ *ith tharilable otiectiVe5 at tr*disc¥ebcffl olthe tr￿tee$. Re5trictd funds ron only be uxd lerf pa￿.￿￿￿r re5trida* purwses *ithin the obj.ects Lrf the d*rity. Re5trcts"or 8ri% specThled by dorwut*then funds are raisèj *Jr P*b.￿laT f8Sknded purposes. Fyrlhwe¥pknabw of Ihe nalwg pwpose fwKI 15 FrYJwJed inthe r*Xe5 b) thofirMJKA statW￿l￿. Hlrt purchase ièaslng commhmerts R*tsts under aptrairy Itasès are chwged to th• Slaemthit d Finanoal Adi%ilie8 on a straTrJht &n¢ th¢ p*iod ofthe lease. The ¢haiitsbl* ¢thmp8ry op¥&tes a defined Culribulir￿ pensKth scl*me. cOrrtrib￿ions PAY8￿* to Ih ch*"tat4e corrpanls p￿1(￿ charged to th¢ 9otemwt of Financkal in th& PWk)d lo ralBIe. Page 15 Foll1￿1•r L>Thphtyna F¢Jundatlon Ilotes Igthe Rnandal Slatem•nis- conllnued fortTre ￿r•ftdert 31 December 2022 A¢¢ouniiThJ pol1de5-￿nt1nWId $lgnlll¢antludgernent aTrd estbNt•s Prepara*'C￿ ol the 51alements I￿￿re5 to make styanffjcart judgements and e5tYnzt85 in d¢twrnThng the car￿lyj •nounts d ac¢ru8ls and deferred Man•Y￿ent m8kes as5umF4ion5 Qf the Off￿tS cl u￿rtan f￿r8 a¥￿ts on a6sets and liab"lrti86 at tho Sheet date. Th8 manag￿en¢8 estimates and assurnpi￿ are ba5•d ly'￿1￿¢¥ ev1￿ce and &weclatw ￿ fvture events and are rewewed pul0d￿lly. TP4s (b'sdosw& 8Xd￿ u￿ta￿ty fvIL¥e events and Jud￿ent in res￿ of measwng finantial instruments. Manag*nent do nrl oYAider th8nE 10 be ty mat&yW or esknab'cffj urKwtwnty requlri di8d3sur•. Flnanclal Instruments Finana81 assets and fir£ni¥￿ lablth"¢s we re¢¢$r1￿ in th¢ W•K¢ ¢h•rity becomes • p•rty lo the wnlraLthd prwgowts ¢rfthe 1￿ment olher *Jebtors ond u&Jifors we da5sfiwJ as ￿"¢ finw¥ instrum¥ts measw¢d at initial reLyyJnilwx al tr#n50¢b"th prica. Debtors creditu5 SubwU￿￿Y mtyaswed at *horftsad COSE using th• off8¢tive intwesl rate meth)d. A yo¥isic*n is esiai4*1*d ￿ tWe is (*¥ethe Ihal Ihe be ￿¢10 cd all ¥mtturts due. Cash cash etymlents We dasslled •$ basic fjmnaal ¥8truments and C￿[*1￿• cash in and at b8nk and bar* ovwdralts are an int•Jal wlofthe Gh¥itw$ cash FInana￿ li*ilib¢s Ir￿tr￿ is>A by Ihe chwty are classified in arx0rd8￿ wrth the subslance of the ¢ontracbj￿ ent¥•Y into and ￿ defiritions of a finArwial lJ"at•"lty an equrty insbument. An equity instrument is any o)rtrxl Ihal ￿thnrAs a re5￿ul irtwe5t in the assèts of the tharity after deducting al Of rts lah"lth"¥s. Eqitify instrum6ntS Issu￿ bytha tharty are r¢cordwJ at the pro¢¢eds r￿4ved. not ol thr8ct issue Donatlons and Itya¢tes 2022 2021 Eh)nation¥ 1.678 785 Donations and legaLyes wK4ude resrrm*J irKane r*aved of£200,(W *)r SL￿￿ aThJ than¢￿eThI treatsne￿ and ￿reS fr* FL tht e5tailistrmt¥rt of a Paliurt FL Rw'5try and Bicbank. 2022 2021 DepJ5it ac¢tyJnt irtuest 37 PagB 16 Folllular L￿￿phornI Found#l¢)n Not*5 tothe Anancl81 Statements. conllnued for the yeorended 31 Owmbtr 2022 Ral$•TrJ fvnd$ RalslThJ donalons and l•gaeles 2022 2021 Staff ¢osls Mwketing and Crynmun**hinS Event Consultancy IT anL1 support co AJl(*ATron 01￿￿eats Trovel Evenl eosls FUndra￿Tra les 86,929 37,023 20.492 3.254 24.485 25.403 fj9. 4e9 20.659 1.304 10,966 318,566 106,992 Investhient m4nto¢ment ¢0gts 20 A9ty0gate amwnts 330,453 Chorflablt *¢Uvlll•s ¢0Sts CURE FL Olr•¢l grant C95ts Isee note ei Swrt costs l$e• ntste n Totals "rect Expendi GOverna￿e Gosts Support costs 736.834 B03.501 369.398 16,302 1.929,733 16.302 133,677 756.834 2079712 CURE FL qrnnt award 2022 2021 CLIRE FLF Grant aw•d CURE FL Man4gem￿t C4Jsts e03.501 232 294 1035.795 The iota gw15 paNI lo instthApxsdurirvJ Ihe yoar was a5 kn. 2022 2021 G￿￿al (uThJ Pago 17 Follkwlaw L￿Thph￿a F4yJThl*lon Not•s to Flrwidal *alemwrt5. ¢ontlnu fortheyear endtd 31 DeeernLW 2022 Support Casts Other Totsfs Direct Expendiiwe 113,28n 16.302 369.398 16,302 986171 Support Costs 178.501 39.353 287 083 Net In¢omell•xi￿dl1urnl Net Irwn￿(eWdrt￿¢j B *led aftèr (MirWI(x•thbt¥Jl'. 2022 2021 Audit￿￿. remuneration 15.056 17.251 2.578 Hireof plant and 367 810 ded 31 De¢￿ber 2021. Trustees. expenses There wer• no truslee5' ewnses pgrd (or th• >*w 31 0￿M￿bIT2022 nor for ywr ￿ded 31 De¢¢mbtr 2021. Donatlons frorn Tru5t•qs' During Ihe pwiodtre ￿ agJwate •wuntoldmaknns trrffl Trustees £9.(W12021: £10.1)Jo}. 10. Staff costs Th• averaye Thmber Of￿￿oyeeS duri￿ Ihe yearwa5 5{2W21-41. Th• aver4e number demrAoyÉes duriry tr*yèarwas a$fokn**" 2022 2021 Athnin 2021 eeQ.CQi- £70,¢X £70.W1 . £80,( .c()1- £9],( £101.C((1- £110.Q 18 Folllalar L)Thph¢m• Fwnd*lon Notes tolhe Fln•ndal Statements. ¢ontlnued forthe year endtd 31 Decemijer 2022 11. Tanglble fixed assets Computer equlpm*nt Cosi At 1 January XQ2 ibms . 10.216 At 31 oK￿ber 2022 14.816 Al 1 2￿2 Charge f(￿year 4.520 3.263 At 31 Oe¢emt* ZQ22 Nèt Ix*ok value At 31 Oecemt*r 2022 7.033 Al 31 Oewnber 2021 5.696 11 Debtors: aM+)￿ts lallln9 due wllhln fft yew 20Z2 2021 Trndtr debtors Qlher debttys Prepayments and irthme s).ocKJ 20.346 11 Cr•dltor&' falllrffj •kn T*lthln year 2022 2021 Bank loans o¥erdraft5 I￿ 14) Trade Cr￿11 16.401 211,334 25.135 17 851 14.833 9.449 21 438 l& Loans An ￿¥ty5￿5 d the maturity cl kJa￿ 15 belw. 2022 2021 rnwnts faling *thin¢Thyèar on Bank overdrafts Pwjb 19 Folll¢ulw L￿nph1Tha Foundatlon Not05 to th• RnarKlal Statements.conllnued Tor the yearendea 31 De¢anbef 2022 Analjryls ol nèt assets bet*wi funds 2022 Totsl 2021 Total funds nd5 Fixed 855816 Ojrrent assets Current *ab¢th"es 7,033 1,455.609 270.7211 5.696 1.439.249 {16.4011 1,439.208 1 191.921 16.401 1 175520 1.399.425 Movement In fund movwnent In lunds Al 111122 31112122 Unrestricttd General lund 1.399.425 I207.￿) 1,191.921 Restr￿¢￿ 118,4011 TOTAL FUNDS 1.399.425 223,9)51 1,175.520 Net mo¥￿ent irb fwds. irKWvJ n the abrye areas Idkx5." IrK¢mlng Resoure•s Mov•ment lTrfunds Unrestrlcted funds Gen¥al Ivnd 1,986.260 12.193.784) 1207,5041 R•strkted furrf Resrrid 1216.4011 116.4011 TOTAL FUNOS cOm￿ra11¥•$ for mo¥•m•rt In funds Net mtrv¢ment In funds At 31M2121 At 111ll1 Unrestrl¢ted fvnds Gen¥al fvnd 356.337 1,043,088 1,399.425 TOTAL FUNDS 13￿425 F•lIk￿l¥ LyTnph•w F•und4lt Nths to the Flnaftdal Statem*bts. ¢OnllNed fortheyearended 31 Decemtxr2Q22 MoveThnt th funts-¢ontlnued In lund5 General fvjnd 1.678.822 1635.734} 1,043.088 TOTAL FUNDS 1.678.822 635.734 1,043.086 A current yew 12 Mont￿ year 12 cryrt>vwd os t￿. Net movement In funds At 31n2Q2 At 111r21 G￿¥21 bJThJ 356.337 B35.584 1.191,W21 Re5tr1¢t•d lunds Reslrthj 116.4011 110.4011 TOTAL FUNDS A cwrent year 12 mtffilhs and year 12 mths n81 Eno￿￿1 In knds. inc4ty*J in thg are In funrts Unrestrlthd fund5 Gwwal fijnd 3.065.0tr2 12.e29.4981 835.584 R•stricied funds 2￿.Th?0 1216.4011 116.4011 TOTAL Fi￿Os 819 183 17. Related partydsdo5ur•¥ FollknJlar L5￿Ph￿* Found￿On Tort￿Yearended 31 Decemlxr 2022 18. Uabl￿ty ol mem1*5 charilatAe CLryany is lini1￿ by yrarte¢ and hos ¥1 tr* oftha dwi18tlo C¥Jnpany ny wound.up, the IAtiity in Ih• hmrt•J lo £10 w rn￿b￿ of the charila￿e ctynpaThy during Ihe tine they are a rnwnber or year of ceasirg to be a rn¥nber. 85 Staled fft ihe Memorandurn •nd hjtidos ofA66ou'ation. Pape 22